Cara Therapeutics, Inc. (LON:0HTC)

Market Cap	19.25M
Revenue (ttm)	5.70M
Net Income (ttm)	-56.61M
Shares Out	n/a
EPS (ttm)	-12.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48
Average Volume	89
Open	16.55
Previous Close	16.78
Day's Range	15.75 - 17.10
52-Week Range	0.50 - 5.82
Beta	n/a
RSI	55.17
Earnings Date	May 12, 2025

About Cara Therapeutics

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi P...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HTC

Financial Performance

In 2024, Cara Therapeutics's revenue was $7.14 million, a decrease of -65.96% compared to the previous year's $20.97 million. Losses were -$70.87 million, -40.20% less than in 2023.

Financial numbers in USD